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LETTERS TO THE EDITOR
Is it Time to Reevaluate
the Role of Surgery in
Small Cell Lung
Cancer?
To the Editor:
Unusual results of surgical treat-
ment in small-cell lung cancer (SCLC)
patients were published by Lim et al.1
in the article “The role of surgery in he
treatment of limited disease small cell
lung cancer. Time to reevaluate” in the
October issue of the Journal of Tho-
racic Oncology. In the group of 59
completely resected SCLC no patient
had any documentation of preopera-
tive chemotherapy, 13 patients had re-
ceived adjuvant chemotherapy, two
patients adjuvant radiotherapy, and
one adjuvant chemo-radiotherapy. De-
spite this, the 5-year survival rate was
52%! This calculated (not observed)
percentage of survival is quite com-
prehensible considering the median
time to follow-up was only 2.8 years.
Less acceptable is the paradoxical
statement of survival by Union Inter-
nationale Contre le Cancer (UICC)
clinical stage and clinical nodal status:
patients with a more progressed stage
had better survival. The results were
similar when the pathologic stage was
used for analysis. So, the authors state
that “UICC classification had a poor
discriminatory value for prognosis,” “the
influence of nodal involvement was un-
clear; the best prognostic subgroup was in
patients with N2 disease.”
The prognostic value of UICC
tumor node metastasis staging in
SCLC has been established in many
clinical studies. In the International
Society of Chemotherapy-Lung Can-
cer Study Group, multinational, pro-
spective, and randomized study of 183
SCLC patients treated surgically,
which also included patients from Slo-
venia, the N0 patients had a signifi-
cantly better survival rate than the N1
and N2 patients.2
Lim et al. did not explain their
unusual observations. Searching for a
reason for such results, there is (beside
accidental findings due to the small
number of individual groups of pa-
tients) a reasonable possibility that
patients in a higher stage more fre-
quently received adjuvant therapy that
could have led to better survival. From
this point of view, the published study
actually evaluated the role of adjuvant
therapy in resected SCLC.
A solitary limited pulmonary tu-
mor without enlarged regional lymph
nodes and without suspicion of distant
metastases represents a challenge for
the thoracic surgeon, even in the case
of confirmed SCLC. In the literature,
one finds data on successful surgical
treatment of SCLC without chemo-
therapy, but the survival rate of such
cases is low. This is substantiated by
the survival rate in the period before
routine use of chemotherapy. With the
present knowledge of SCLC, the omis-
sion of adjuvant chemotherapy is too
risky, whether the chemotherapy is ad-
juvant therapy to surgery or surgery
adjuvant to chemotherapy.
Based on our own experience in
Slovenia,3 as in many thoracic centers
world wide, surgery and chemotherapy
are routinely performed in the case of
selected small, solitary, preferably pe-
ripheral SCLC after consistently being
carried through complete staging.
Still, the percentage of such cases is
very low.
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Response to Letter to
the Editor
In Response:
We thank Dr. Debevec for his in-
sightful comments and the opportunity
to clarify a number of points from our
work. The survival estimates are derived
from Kaplan Meier methods, which rep-
resent actuarial survival, the standard
method for reporting and as such there
should not be any controversy.
In our small series, we are sim-
ply stating the observation that the
International Union Against Cancer
tumor, node, metastasis staging had
poor discrimination for survival in the
patients that made up our cohort, we
are in no way implying that the staging
system itself is poor. We acknowledge
in our article that this may simply be due
to small sample size.
Our article is a cohort study, and
we reported excellent survival, unfor-
tunately we do not have a robust ex-
planation to account for this. One lim-
itation was that we have a very wide
referral base and as such we are not
certain if patients that had been dis-
charged from our care received further
adjuvant treatment locally.
Our results question the prevail-
ing thinking that all patients with small
cell lung cancer, except those in the earli-
est stages, should be considered only for
chemo-radiotherapy. We hope that more
international centers will review and
publish their 5-year survival results to
provide further information and we are
currently proposing a clinical trial that
we hope will be able to provide a more
robust answer to some of the questions
that have been raised.
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